Celldex Therapeutics CLDX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -18,587.7%-15,809pp | -2,778.9%-534pp | -2,245.3%+2,644pp | -4,889%-3,358pp | |
| Net margin | -16,737.2%-14,488pp | -2,248.8%-194pp | -2,054.8%+2,711pp | -4,765.6%-3,250pp | |
| EBITDA margin | -18,369.1%-15,635pp | -2,733.6%-532pp | -2,201.6%+2,565pp | -4,766.1%-3,301pp | |
| Free cash flow margin | -13,820.1%-11,545pp | -2,274.9%-690pp | -1,585.2%+2,893pp | -4,478.6%-3,142pp | |
| Returns | |||||
| Return on equity | -40.6%-13.8pp | -26.8%+10.6pp | -37.4%-7.3pp | -30.1%-7.7pp | |
| Return on assets | -37.6%-12.5pp | -25.1%+9.5pp | -34.6%-6.4pp | -28.2%-7.4pp | |
| Return on invested capital | -47%-12.1pp | -34.9%+9.4pp | -44.3%-10.6pp | -33.7%-7.9pp | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 10.5×-8.4× | 18.9×+5.0× | 13.9×-3.2× | 17.1×-7.8× | |
| Quick ratio | 10.5×-8.4× | 18.9×+5.0× | 13.9×-3.2× | 17.1×-7.8× | |
| Cash ratio | 0.6×-0.2× | 0.7×-0.4× | 1.1×-0.5× | 1.6×-0.8× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $7.94-31.6% | $11.60+31.0% | $8.86+27.3% | $6.96-28.9% | |
| Valuation | |||||
| Market capitalization | $1.8B+7.6% | $1.68B-22.7% | $2.17B+3.3% | $2.1B+16.4% | |
| Enterprise value | $1.78B+7.6% | $1.65B-22.7% | $2.14B+3.0% | $2.07B+17.4% | |
| Price / sales | 1,167.4×+929× | 238.8×-76.3× | 315.1×-576× | 890.6×+503× | |
| Price / book | 3.4×+1.2× | 2.2×-2.8× | 5.1×-1.4× | 6.4×+2.1× | |
| EV / sales | 1,150.2×+915× | 235.3×-75.1× | 310.4×-569× | 879.9×+500× | |
| Free cash flow yield | -11.8%-2.3pp | -9.5%-4.5pp | -5%0.0pp | -5%-1.6pp | |
| Earnings yield | -14.3%-4.9pp | -9.4%-2.9pp | -6.5%-1.2pp | -5.4%-1.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Celldex Therapeutics's ratios come from?
- Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
